Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress Mim8 prophylaxis treatment ...

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific ...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and ...

Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout ...

The attack data in RAPIDe-3 have continued to accrue following the achievement of target enrollment in the study; we now estimate that our RAPIDe-3 topline data announcement will be in the fourth ...